Home / Psoriasis (page 25)


Here you will find the latest clinical research on psoriasis.

Healthcare Expenditures of Psoriasis Examined

Psoriasis healthcare costs

In 2012, the top 10% (T10) of psoriasis patients accounted for nearly 40% of overall healthcare expenditures among enrollees with psoriasis in a US health plan, a recent study found. Researchers conducted a retrospective study of patients with psoriasis with continuous enrollment in a plan from January 1, 2011, to December 31, 2013. Demographics, comorbidities, …

Read More »

Risankizumab tops ustekinumab in phase II psoriasis trial

Psoriasis treatment

Key clinical point: Clinical responses in psoriasis patients treated with risankizumab were superior to responses in patients treated with ustekinumab. Major finding: At 12 weeks, 77% of risankizumab patients showed a 90% or greater reduction in PASI score, compared with 40% of ustekinumab patients. Data source: A phase II randomized …

Read More »

What’s old is new in topical psoriasis therapy

psoriasis therapy

Key clinical point: A fixed combination of halobetasol and tazarotene formulated as a lotion proved successful in phase II and is now being evaluated in a large phase III study. Major finding: An investigational fixed-combination lotion consisting of halobetasol propionate 0.01% and tazarotene 0.045% achieved scores of clear or almost …

Read More »

$790M Deal Reached For Potential Psoriasis Treatment, AST-005

AST-005 Purdue

Purdue Pharma and Exicure have announced a strategic research alliance and licensing agreement for AST-005, a potential treatment for psoriasis and other diseases amenable to a gene regulation approach by Exicure called spherical nucleic acid (SNA) technology. Purdue will own full global rights to AST-005, among other collaboration targets. Together with …

Read More »